EUCTR2007-003578-24-DE进行中（未招募）不适用
A single-centre, open-label, randomised explorative pharmacokinetic/pharmacodynamic study of the gonadotropin-releasing hormone receptor antagonist degarelix (FE 200486) in patients with benign prostatic hyperplasia - FE 200486 CS25
适应症
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- Male
入选标准
- •1.A signed written informed consent before any study related activity is performed.
- •2.Man, 45 to 75 years of age.
- •3.Clinical diagnose of BPH with a prostate volume more than 30 mL, a maximal uroflow of 12 mL/sec or less and an IPSS of 13 or more at screening. See Section 7.1.4 for a description of the assessments.
- •4.A PSA value less than 10 ng/mL and no clinical evidence of adenocarcinoma of the prostate at screening. If a biopsy of the prostate is performed, a period of 6 weeks should be allowed after the biopsy before the patient is enrolled into the study.
- •5.Has a baseline testosterone level above 3 ng/mL at screening.
- •6.A Body Mass Index (BMI) between 18 kg/m2 and 32 kg/m2 and a body weight between 50 kg and 120 kg.
- •7.Has negative serology for Human Immunodeficiency Virus (HIV) 1, HIV 2, hepatitis B surface antigen, and hepatitis C virus antibody.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1.Previous surgery of the prostate.
- •2.Previous treatment with GnRH agonists or GnRH antagonists.
- •3.Treatment with 5-alpha reductase inhibitors, e.g., finasteride (Prosca®)or dutasteride (Avodart®) within the past 12 months before the study.
- •4.Treatment with alpha-adrenergic antagonists, e.g., terazosin, doxazosin, tamsulosin, alfuzosin (see Appendix 4) within 2 weeks prior to Screening part II (or Part I, if IPSS is performed at Screening part I).
- •5.A clinically significant neurological, gastrointestinal, renal, hepatic cardiovascular, psychological, pulmonary, metabolic, endocrine, haematological, dermatological or infectious disorder or any other condition including excessive alcohol or drug abuse, which may interfere with trial participation or which may affect the conclusion of the study as judged by the investigator.
- •6.Diagnosed cancer within the last 10 years except for adequately managed basal cell carcinoma and squamous cell carcinoma of the skin.
- •7.Present or a history of severe allergy or anaphylactic reactions.
- •8.A history of hypersensitivity to or is hypersensitive to any component of the investigational medicinal product.
- •9.A significant acute illness within two weeks prior to screening.
- •10.Any clinically significant laboratory abnormalities, which in the judgement of the investigator would interfere with the patient’s participation in this study or evaluation of the study results. Liver transaminases must be within normal limits.
- •11.Treatment with any drug modifying the testosterone level (see Appendix 3) or function within 12 weeks before Screening visit part II (or Part I, if IPSS is performed at Screening part I).
- •12.Donation of more than 700 mL blood within the last 10 months before the start of study.
- •13.Has a mental incapacity or language barriers precluding adequate understanding, co-operation, and compliance.
- •14.Is considered by the Investigator unsuitable to participate in the study for any other reason.
- •15.Has received an investigational medicinal product within the last one month for single dose studies (otherwise three months) before entering the study or longer if judged by the investigator to possibly influence the outcome of the current study.
研究者
相似试验
进行中（未招募）
不适用
A single-center, prospective, open-label, randomized, comparative, and placebocontrolled observation study for effect of using Mobile App-based Human Coaching Program on NAFLDDiseases of the digestive systemKCT0007695Yonsei University Health System, Severance Hospital100
尚未招募
Unknown
A single-center randomized, open-label, prospective study to evaluate efficacy and safety of DDK(Drug delivery kit, Welpass) for pain relief after gynecologic laparotomy surgeryKCT0008852Asan Medical Center110
招募中
Unknown
A prospective, open-label, single-centre, randomized study to evaluate coronary microcirculation in de-novo lesions treated with drug-coated balloons or drug-eluting stentsCoronary artery diseaseJPRN-UMIN000052443Other50
已完成
不适用
A single-center, prospective, randomized, open-label, clinical trial of ceramide 2-containing hydrocolloid dressings versus polyurethane film dressings for pressure ulcer prevention in high-risk surgical patientsPressure ulcerJPRN-UMIN000019420Pressure Ulcer Committee of Tokyo Medical University Ibaraki Medical Canter128
尚未招募
4 期
A prospective, single-center, randomized, open-label, parallel-controlled clinical study on the efficacy and safety of Shenfu Injection in the treatment of septic shock (Syndrome of Yang-Qi collapse)Septic shockITMCTR2200006718Dongfang Hospital Beijing University of Chinese medicine